Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allarity Therapeutics, Inc. - Common stock (NQ:ALLR)

0.8890 -0.0710 (-7.40%)
Streaming Delayed Price Updated: 1:04 PM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allarity Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert ↗
U.S. stock futures were swinging between gains and losses on Tuesday after a mixed session on Monday. Futures of major benchmark indices were mixed in premarket trading. President Donald Trump‘s... 
Via Benzinga
Topics World Trade
News headline image
XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday ↗
 
Via Benzinga
News headline image
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week ↗
Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among... 
Via Stocktwits
News headline image
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
ALLR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
ALLARITY ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Allarity Therapeutics to Contact Us to Have Their Losses Evaluated Today
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Allarity, ZoomInfo, and Agenus and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.